P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY

• H. Einsele,
• B. Dhakal,
• J. M. Schecter,
• T. Roccia,
• W. Deraedt,
• N. Lendvai,
• A. Slaughter,
• C. Lonardi,
• K. Connors,
• K. Qi,
• A. Londhe,
• R. Carson,
• J. Voelker,
• P. Cost,
• S. Valluri,
• E. Florendo,
• L. Pacaud,
• K. Yong

Affiliations

H. Einsele

1 University Hospital of Würzburg, Würzburg, Denmark

B. Dhakal

2 Medical College of Wisconsin, Milwaukee, WI, USA

J. M. Schecter

3 Janssen Research & Development, Raritan, NJ, USA

T. Roccia

4 Janssen Global Services, Raritan, NJ, USA

W. Deraedt

5 Janssen Research & Development, Beerse, Belgium

N. Lendvai

3 Janssen Research & Development, Raritan, NJ, USA

A. Slaughter

6 Cilag GmbH International, Zug, Switzerland

C. Lonardi

7 Janssen, Buenos Aires, Argentina

K. Connors

3 Janssen Research & Development, Raritan, NJ, USA

K. Qi

8 Janssen Research & Development, Titusville, FL, USA

A. Londhe

8 Janssen Research & Development, Titusville, FL, USA

R. Carson

9 Janssen Research & Development, Wayne, PA, USA

J. Voelker

10 Janssen Scientific Affairs, LLC, Horsham, PA, USA

P. Cost

4 Janssen Global Services, Raritan, NJ, USA

S. Valluri

4 Janssen Global Services, Raritan, NJ, USA

E. Florendo

11 Legend Biotech, Piscataway, NJ, USA

L. Pacaud

11 Legend Biotech, Piscataway, NJ, USA

K. Yong

12 University College London Cancer Institute, London, United Kingdom